Luippold Gerd, Beilharz Martina, Wehrmann Manfred, Unger Liliane, Gross Gerhard, Mühlbauer Bernd
Department of Pharmacology and Toxicology, Faculty of Medicine, University of Tübingen, Wilhelmstrasse 56, 72074 Tübingen, Germany,
Naunyn Schmiedebergs Arch Pharmacol. 2005 May;371(5):420-7. doi: 10.1007/s00210-005-1030-1. Epub 2005 May 11.
Dopamine D2-like receptors, including D2, D3, and D4 receptors, are involved in the regulation of glomerular hyperfiltration due to diabetes mellitus. These hemodynamic alterations represent a risk factor for the later development of diabetic nephropathy. The aim of the present study was to determine whether the D3 receptor subtype modulates the diabetes-induced increase in glomerular filtration rate (GFR) in rats. Renal function was studied in Sprague-Dawley rats 14 days after induction of a moderate diabetes mellitus (DM) by streptozotocin and in non-diabetic controls (CON). Rats were orally treated either with the peripherally acting, selective dopamine D3 receptor antagonist BSF 135170 (BSF, 10 mg/kg per day for 2 weeks) or with vehicle (VHC). Perfusion-fixed kidneys were used for estimation of glomerular volume. In conscious rats, which were treated with BSF, the DM-induced increase in fluid intake, urinary output, and renal sodium excretion was significantly less pronounced than in the vehicle group (DM-VHC). In the clearance experiments, GFR in CON was about 0.84+/-0.04 ml/min per 100 g body weight. The DM-VHC group presented a significant glomerular hyperfiltration (1.09+/-0.04 ml/min per 100 g body weight). Treatment with BSF significantly lowered GFR towards levels of CON. The estimated glomerular volume was 0.73+/-0.03 x 10(6) microm3 in the CON-VHC group and 0.86+/-0.04 x 10(6) microm3 in the DM-VHC animals. Interestingly, treatment with BSF decreased the glomerular volume in both groups. Irrespective of BSF treatment, kidney wet weight related to body weight was about 36% higher in DM animals compared with CON animals. We conclude that dopamine D3 receptors represent a target for the modulation of diabetes-induced glomerular hyperfiltration. Therefore, the results encourage the testing of the possible beneficial effects of long-term D3 receptor blockade on the development of diabetic nephropathy.
多巴胺D2样受体,包括D2、D3和D4受体,参与了糖尿病所致的肾小球高滤过调节。这些血流动力学改变是糖尿病肾病后期发展的一个危险因素。本研究的目的是确定D3受体亚型是否调节糖尿病诱导的大鼠肾小球滤过率(GFR)升高。在通过链脲佐菌素诱导中度糖尿病(DM)14天后,对Sprague-Dawley大鼠及非糖尿病对照(CON)大鼠的肾功能进行了研究。大鼠口服外周作用的选择性多巴胺D3受体拮抗剂BSF 135170(BSF,每天10 mg/kg,共2周)或赋形剂(VHC)。灌注固定的肾脏用于估计肾小球体积。在接受BSF治疗的清醒大鼠中,DM诱导的液体摄入量、尿量和肾钠排泄增加明显低于赋形剂组(DM-VHC)。在清除实验中,CON组的GFR约为每100 g体重0.84±0.04 ml/min。DM-VHC组出现明显的肾小球高滤过(每100 g体重1.09±0.04 ml/min)。用BSF治疗可使GFR显著降低至CON组水平。CON-VHC组估计的肾小球体积为0.73±0.03×10⁶μm³,DM-VHC组动物为0.86±0.04×10⁶μm³。有趣的是,用BSF治疗可使两组的肾小球体积减小。无论是否接受BSF治疗,与CON组动物相比,DM组动物的肾湿重与体重的比值约高36%。我们得出结论,多巴胺D3受体是调节糖尿病诱导的肾小球高滤过的一个靶点。因此,这些结果促使人们测试长期阻断D3受体对糖尿病肾病发展可能产生的有益作用。